BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:30 PM
 | 
Sep 27, 2012
 |  BC Extra  |  Clinical News

Achillion gains on HCV data, pipeline update

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $0.81 to $10.30 on Thursday after reporting that ACH-3102 showed enough anti-HCV activity in a Phase Ib trial that it began a Phase II trial of the compound as part of an all-oral, interferon-free...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >